On this page
Draft rule from 28 September extends prior-sanction ad curbs on Schedule H, H1, X drugs to retailers, wholesalers
India's Health Ministry notified draft rules on 28 September 2026 under G.S.R. 861(E), extending prior-sanction requirements for advertising Schedule H, H1 and X drugs to retail and wholesale licence holders. Public objections are open for 30 days.
Get the 07:30 IST India retail brief
One email each morning: the day’s top moves in Indian retail, why each matters and what to watch. Free. Stop any time.
The numbers
Figures from PIB India
| New provision proposed: | sub-rule (22) under Rule 65 |
|---|---|
| DTAB meeting that recommended change: | 93rd, 16 February 2026 |
Why it matters to operators and investors
Pharmacy retailers and wholesalers should stop any promotion of Schedule H, H1 and X drugs unless prior sanction is secured, since the draft sub-rule (22) under Rule 65 would make it a licence condition, and the 30-day objection window is the time to push back.
What to watch next
- Public objections or representations from pharmacy and e-pharmacy bodies before the 30-day window closes
- A final Gazette notification of sub-rule (22) under Rule 65, and any change from the G.S.R. 861(E) draft wording
- Another DTAB meeting that takes up the advertising provisions
- Guidance from the ministry or state drug controllers on how prior sanction is applied for and what counts as advertising
- Visible changes to Schedule H, H1 and X drug promotions on major online pharmacy platforms or chain storefronts
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Pharmacy retailer and wholesaler associations are likely to file written objections within the 30-day window. They will probably focus on how 'advertising' is defined and on the sanction workload.
- The Health Ministry is likely to consider the objections and then notify final rules. It would probably keep the prior-sanction principle that came out of the DTAB's 93rd meeting on 16 February.
- Online pharmacy platforms and large chains may quietly tighten how they promote Schedule H, H1 and X drugs, including discounts, app banners and search promotions, before the rules are final.
- State drug regulators are likely to take on enforcement once the rules are final. Early attention will probably fall on promotions that name prescription-only drugs.
- Pharmaceutical manufacturers may adjust trade-promotion and retailer-facing marketing for scheduled drugs to avoid compliance exposure through their distribution partners.